| Clinical data | |
|---|---|
| Other names | Long R3-IGF-1; IGF-1 Long R3 |
| Routes of administration | Injection |
| ATC code |
|
| Pharmacokinetic data | |
| Eliminationhalf-life | 56-72 hours |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C400H625N111O115S9 |
| Molar mass | 9117.60 g·mol−1 |
Long arginine 3-IGF-1, abbreviated asIGF-1 LR3 orLR3-IGF-1, is asyntheticprotein and lengthenedanalogue ofhumaninsulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses anarginine instead of aglutamic acid at the third position in itsamino acid sequence ("arginine 3"), and also has an additional 13amino acids at itsN-terminus (MFPAMPLLSLFVN) ("long"), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains thepharmacological activity of IGF-1 as anagonist of theIGF-1 receptor, has very lowaffinity for theinsulin-like growth factor-binding proteins (IGFBPs), and has improvedmetabolic stability.[1][2] As a result, it is approximately three times morepotent than IGF-1,[3] and possesses a significantly longerhalf-life of about 20–30 hours (relative to IGF-1's half-life of about 12–15 hours).[4]
Theamino acid sequence of IGF-1 LR3 is MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA.[5]
 | Thishormonal preparation article is astub. You can help Wikipedia byexpanding it. |
